Pharsight

Drugs that contain Avapritinib

1. Ayvakit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9994575 BLUEPRINT MEDICINES Compositions useful for treating disorders related to kit
Oct, 2034

(10 years from now)

US9944651 BLUEPRINT MEDICINES Compositions useful for treating disorders related to kit
Oct, 2034

(10 years from now)

US9200002 BLUEPRINT MEDICINES Compositions useful for treating disorders related to KIT
Oct, 2034

(10 years from now)

US11827642 BLUEPRINT MEDICINES Compositions useful for treating disorders related to KIT
Oct, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-863) Jun 16, 2024
New Chemical Entity Exclusivity(NCE) Jan 09, 2025
New Indication(I-864) Jun 16, 2024
Orphan Drug Exclusivity(ODE-356) Jun 16, 2028
Orphan Drug Exclusivity(ODE-434) May 22, 2030
Orphan Drug Exclusivity(ODE-366) Jan 09, 2027
New Indication(I-912) May 22, 2026

NCE-1 date: 10 January, 2024

Market Authorisation Date: 16 June, 2021

Treatment: Treatment of advanced systemic mastocytosis, including patients with aggressive systemic mastocytosis (asm), systemic mastocytosis with an associated hematological neoplasm (sm-ahn), and mast cell leu...

Dosage: TABLET;ORAL

More Information on Dosage

AYVAKIT family patents

Family Patents